Novartis announces phase III study of Jakavi in chronic graft-versus-host disease met primary and key secondary endpoints

Novartis announces phase III study of Jakavi in chronic graft-versus-host disease met primary and key secondary endpoints

Source: 
Pharmaceutical Business Review
snippet: 

Novartis announced that the Phase III REACH3 study evaluating Jakavi® (ruxolitinib) in patients with steroid-refractory or steroid-dependent chronic graft-versus-host disease (GvHD) met its primary endpoint of superior overall response rate (ORR) at Week 24 versus best available therapy (BAT).